VOYAGER THERAPEUTICS INC (VYGR)

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024

VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Voyager Therapeutics (NASDAQ:VYGR) just reported results for the first quarter ...

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single...

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and...

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...

Commit To Purchase Voyager Therapeutics At $5, Earn 12.4% Annualized Using Options

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against...

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Breaks Below 200-Day Moving Average - Notable for VYGR

Investors Snag VYGR Even Cheaper Than Its Secondary Stock Offering

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20

With so many thousands of securities available, there are bound to be compelling ideas for value stocks under $20.

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning!

Voyager Therapeutics GAAP EPS of $1.25 beats by $1.54, revenue of $90.06M beats by $69.42M (NASDAQ:VYGR)

Voyager Therapeutics beats expectations with strong Q4 earnings, reporting significant revenue growth.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and...

VYGR Makes Bullish Cross Above Critical Moving Average

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable...

Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Commit To Buy Voyager Therapeutics At $5, Earn 6.5% Annualized Using Options

Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024

The 2024 investment trends are slowly making themselves known. Make sure you follow our guide to stay ahead of the curb.

Investors Snatch VYGR Even Cheaper Than Its Secondary Stock Offering